Joint (NASDAQ:JYNT) Announces Earnings Results

Joint (NASDAQ:JYNT) released its earnings results on Thursday. The company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05, FiscalAI reports. The business had revenue of $15.18 million during the quarter, compared to the consensus estimate of $14.57 million. Joint had a return on equity of 11.70% and a net margin of 6.49%.

Here are the key takeaways from Joint’s conference call:

• Profitability and cash flow improved sharply: Q2 revenue rose 14% to $15.2 million, Adjusted EBITDA from continuing operations increased to $1.5 million from $88,000, and free cash flow grew $1.6 million to $1.9 million.
• Refranchising is nearing completion, with clinic ownership transfers and management service agreements progressing across the three sale bundles. Once finalized, The Joint expects to have only three remaining company-owned or managed clinics, supporting a more capital-light model.
• Patient retention reached its best level in more than five years following the rollout of flexible membership options, while active-member trends improved sequentially. Management also reported no meaningful patient pushback to price increases implemented at more than 500 clinics.
• System-wide sales declined 3.7% year over year and Q2 comparable sales were negative 2.8%, although management said July and second-half trends were improving.
• The company reduced its 2026 new-clinic opening outlook to 22–26 from 30–35, and expects year-end clinic count to be below 2025 levels as closures and portfolio optimization offset new openings. Full-year guidance was otherwise reiterated, including $12.5 million–$13.5 million of consolidated Adjusted EBITDA.

Joint Price Performance

Shares of JYNT stock traded up $0.11 during mid-day trading on Friday, hitting $8.33. The stock had a trading volume of 104,765 shares, compared to its average volume of 60,308. Joint has a 12-month low of $7.50 and a 12-month high of $11.26. The firm’s 50-day moving average is $8.76 and its two-hundred day moving average is $8.87. The firm has a market capitalization of $118.79 million, a P/E ratio of 30.85 and a beta of 1.10.

Insider Activity at Joint

In other news, major shareholder Charles E. Jobson acquired 127,676 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was purchased at an average cost of $8.57 per share, for a total transaction of $1,094,183.32. Following the completion of the acquisition, the insider directly owned 1,773,479 shares of the company’s stock, valued at $15,198,715.03. The trade was a 7.76% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 30.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JYNT. JCP Investment Management LLC purchased a new position in Joint during the 2nd quarter valued at about $5,526,000. Topline Capital Management LLC lifted its position in shares of Joint by 18.7% in the 2nd quarter. Topline Capital Management LLC now owns 449,204 shares of the company’s stock worth $5,184,000 after purchasing an additional 70,910 shares during the period. Geode Capital Management LLC boosted its stake in shares of Joint by 17.6% during the second quarter. Geode Capital Management LLC now owns 345,330 shares of the company’s stock valued at $3,986,000 after purchasing an additional 51,704 shares in the last quarter. State Street Corp boosted its stake in shares of Joint by 0.8% during the fourth quarter. State Street Corp now owns 292,123 shares of the company’s stock valued at $2,547,000 after purchasing an additional 2,341 shares in the last quarter. Finally, First Foundation Advisors boosted its stake in shares of Joint by 47.8% during the third quarter. First Foundation Advisors now owns 273,759 shares of the company’s stock valued at $2,612,000 after purchasing an additional 88,486 shares in the last quarter. 76.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Joint from a “buy” rating to a “strong-buy” rating in a report on Saturday. Weiss Ratings upgraded shares of Joint from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, June 12th. Finally, Zacks Research cut shares of Joint from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.